Overcoming obstacles in pharmacogenomic strategies for antiplatelet drugs: Are we RAPID enough?

Pharmacogenomics

Volumn 13, Issue 10, 2012, Pages 1105-1108

  So, Derek Yf ^a   Roberts, Jason D ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

clopidogrel; CYP2C192; pharmacogenomic; point of care genetic test

Indexed keywords

ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYTOCHROME P450 2C19; PRASUGREL; TICAGRELOR;

ACUTE CORONARY SYNDROME; ALLELE; BLEEDING; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG EFFICACY; DRUG TRANSFORMATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HEART INFARCTION; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PHARMACOGENOMICS; REVIEW; STENT THROMBOSIS;

ARYL HYDROCARBON HYDROXYLASES; BIOMARKERS, PHARMACOLOGICAL; CLINICAL TRIALS AS TOPIC; GENOME-WIDE ASSOCIATION STUDY; HUMANS; PHARMACOGENETICS; PLATELET AGGREGATION INHIBITORS; THROMBOSIS;

EID: 84865334740     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.84     Document Type: Review

References (20)

1. Mallal S, Phillips E, Carosi G et al. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358(6), 568-579 (2008).
2. Tantisira KG, Lasky-Su J, Harada M et al. Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N. Engl. J. Med. 365(13), 1173-1183 (2011).
3. Mega JL, Close SL, Wiviott SD et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360(4), 354-362 (2009).
4. Roberts JD, Wells GA, Le May MR et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet 379(9827), 1705-1711 (2012).
5. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J. Am. Coll. Cardiol. 49(14), 1505-1516 (2007). (Pubitemid 46517957)
6. Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357(20), 2001-2015 (2007). (Pubitemid 350106708)
7. Bonello L, Tantry US, Marcucci R et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J. Am. Coll. Cardiol. 56(12), 919-933 (2010).
8. Hochholzer W, Trenk D, Fromm MF et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J. Am. Coll. Cardiol. 55(22), 2427-2434 (2010).
9. Shuldiner AR, O'Connell JR, Bliden KP et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302(8), 849-857 (2009).
10. Mega JL, Simon T, Collet JP et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304(16), 1821-1830 (2010).
11. Hulot JS, Collet JP, Silvain J et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J. Am. Coll. Cardiol. 56(2), 134-143 (2010).
12. Simon T, Verstuyft C, Mary-Krause M et al. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 360(4), 363-375 (2009).
13. Xie HG. Genetic variations of S-mephenytoin 4́-hydroxylase (CYP2C19) in the Chinese population. Life Sci. 66(14), PL175-PL181 (2000).
14. Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361(11), 1045-1057 (2009).
15. Mega JL, Close SL, Wiviott SD et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119(19), 2553-2560 (2009).
16. Wallentin L, James S, Storey RF et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 376(9749), 1320-1328 (2010).
17. Reese ES, Daniel MC, Beitelshees AL, Onukwugha E. Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel. Pharmacotherapy 32(4), 323-332 (2012).
18. Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA 306(24), 2704-2714 (2011).
19. Bauer T, Bouman HJ, van Werkum JW, Ford NF, ten Berg JM, Taubert D. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ 343, d4588 (2011).
20. Trenk D, Stone GW, Gawaz M et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (testing platelet reactivity in patients undergoing elective stent placement on clopidogrel to guide alternative therapy with prasugrel) study. J. Am. Coll. Cardiol. 59(24), 2159-2164 (2012).